ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury

BACKGROUND: In contrast with various pre-clinical studies, recent clinical trials suggest that high dose erythropoietin (EPO) treatment following kidney transplantation does not improve short-term outcome and that it even increases the risk of thrombotic events. ARA290 is a non-erythropoietic EPO de...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: van Rijt, Willem G, Nieuwenhuijs-Moeke, Gertrude J, van Goor, Harry, Jespersen, Bente, Ottens, Petra J, Ploeg, Rutger J, Leuvenink, Henri GD
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2013
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3567997/
https://ncbi.nlm.nih.gov/pubmed/23302512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars